COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00071097
Recruitment Status : Completed
First Posted : October 15, 2003
Last Update Posted : September 20, 2016
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland

Brief Summary:
The purpose of this study is to determine the effectiveness, safety, and tolerability (how well the body stands the drug) of an investigational protease inhibitor (PI) called TMC114 given with low dose ritonavir.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: TMC114/rtv Phase 2

Detailed Description:
A phase II randomized, controlled, partially blinded, trial to investigate dose response of TMC114/RTV in HIV-1 infected patients who have previously received all three licensed classes of HIV antiviral drugs (known as nucleoside reverse transcriptase inhibitors (NRTI), nonnucleoside reverse transcriptase inhibitors (NNRTI) and protease inhibitors (PI)), and who are on a stable PI-containing regimen not including an NNRTI may be eligible to participate. Four doses of TMC-114/ritonavir will be studied. 300 patients in the United States and Puerto Rico will participate. The duration of the study is 96 weeks. Randomize to one of 4 treatment groups (TMC114/RTV: 400/100 mg qd; 800/100mg qd; 400/100mg bid; 600/100 bid) or control arm for 24 to 48 wks. Optimal dose (TMC114/RTV 600/100mg bid) open label portion of the study. The trial was extended to include 144Wks of treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 330 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose Response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.
Study Start Date : October 2003
Actual Primary Completion Date : February 2005
Actual Study Completion Date : November 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: 001
TMC114/rtv 400mg TMC114/100mg rtv once daily
Drug: TMC114/rtv
400mg TMC114/100mg rtv once daily

No Intervention: 005
Control Group Control Group, no intervention
Experimental: 004
TMC114/rtv 600mg TMC114/100mg rtv twice daily
Drug: TMC114/rtv
600mg TMC114/100mg rtv twice daily

Experimental: 003
TMC114/rtv 400mg TMC114/100mg rtv both twice daily
Drug: TMC114/rtv
400mg TMC114/100mg rtv both twice daily

Experimental: 002
TMC114/rtv 800mg TMC114/100mg rtv once daily
Drug: TMC114/rtv
800mg TMC114/100mg rtv once daily

Primary Outcome Measures :
  1. To evaluate the dose-response relationship of antiviral activity of the TMC114/RTV dose regimens at 24 Wks in order to determine the optimal dose. [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. To evaluate safety and tolerability over 24 to 144Wks; The durability of the antiviral activity; The effect of functional monotherapy with TMC114 over 2 weeks in different doses; and The dose-response by comparing the different TMC114/RTV dosages. [ Time Frame: 144 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female, age 18 years or older
  • Documented HIV-1 infection
  • Stable PI regimen for at least 8 weeks prior to screening
  • Plasma viral load at screening above 1000 HIV-1 RNA copies/ml
  • Prior use of more than 1 NRTI for at least 3 months
  • Prior use of one or more NNRTIs as part of a failing regimen
  • At least 1 primary PI mutation as defined by the IAS guidelines
  • Treatment with at least 1 PI for a total of at least 3 months
  • Patient has given informed consent

Exclusion Criteria:

  • Presence of any currently active AIDS defining illness except stable cutaneous Kaposi's Sarcoma and Wasting syndrome due to HIV infection
  • Current or past history of alcohol and/or drug abuse which, in the investigator's opinion, would compromise the subject's safety or compliance to the study protocol procedures
  • NNRTI as part of therapy at screening
  • Patients on a treatment interruption at screening
  • Patients for whom an investigational antiretroviral therapy is part of the regimen at screening or the use of any non-antiretroviral investigational agents 90 days prior to screening
  • Hepatitis A, B, or C.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00071097

Layout table for location information
United States, Alabama
Birmingham, Alabama, United States
United States, Arizona
Phoenix, Arizona, United States
United States, California
Beverly Hills, California, United States
Long Beach, California, United States
Los Angeles, California, United States
Oakland, California, United States
San Diego, California, United States
San Francisco, California, United States
West Hollywood, California, United States
United States, Colorado
Denver, Colorado, United States
United States, District of Columbia
Washington, District of Columbia, United States
United States, Florida
Altamonte Springs, Florida, United States
Fort Lauderdale, Florida, United States
Ft Lauderdale, Florida, United States
Miami Beach, Florida, United States
Miami, Florida, United States
Tampa, Florida, United States
Vero Beach, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
Macon, Georgia, United States
United States, Illinois
Chicago, Illinois, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
Springfield, Massachusetts, United States
United States, New Jersey
Camden, New Jersey, United States
United States, New York
Albany, New York, United States
New York, New York, United States
United States, North Carolina
Huntersville, North Carolina, United States
United States, Ohio
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
United States, Pennsylvania
Hershey, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
United States, South Carolina
Columbia, South Carolina, United States
United States, Texas
Dallas, Texas, United States
Galveston, Texas, United States
Houston, Texas, United States
United States, Virginia
Hampton, Virginia, United States
United States, Washington
Seattle, Washington, United States
United States, Wisconsin
Milwaukee, Wisconsin, United States
Buenos Aires, Argentina
Sponsors and Collaborators
Tibotec Pharmaceuticals, Ireland
Layout table for investigator information
Study Director: Tibotec Pharmaceuticals Clinical Trial Tibotec Pharmaceutical Limited
Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Tibotec Pharmaceuticals, Ireland Identifier: NCT00071097    
Obsolete Identifiers: NCT00980928
Other Study ID Numbers: CR006778
First Posted: October 15, 2003    Key Record Dates
Last Update Posted: September 20, 2016
Last Verified: September 2016
Keywords provided by Tibotec Pharmaceuticals, Ireland:
Safety and efficacy
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents